Cost-Effectiveness Analysis of Benralizumab Among Patients with Severe Asthma from the Chinese Societal Perspective
Applied Health Economics and Health Policy · 20.11.2026
DOI: 10.1007/s40258-026-01088-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 20.11.2026. Verfasst von Chaohao Shi und 9 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Pharmacoeconomic Evaluation and Policy Optimization Pathways for Asthma Clinical Treatment under DRG/DIP Frameworks, Development of Intelligent Precision-Based DRG Payment Standards Using OLAP Technology.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- Pharmacoeconomic Evaluation and Policy Optimization Pathways for Asthma Clinical Treatment under DRG/DIP Frameworks
- Development of Intelligent Precision-Based DRG Payment Standards Using OLAP Technology
Zitieren
APA
Shi, C., Tan, C., Wan, X., Wu, M., Meng, K., Li, A., Zhang, Z., Yi, Y., Liu, Q., & Li, J. (2026). Cost-Effectiveness Analysis of Benralizumab Among Patients with Severe Asthma from the Chinese Societal Perspective. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-026-01088-6
Vancouver
Shi C, Tan C, Wan X, Wu M, Meng K, Li A, et al. Cost-Effectiveness Analysis of Benralizumab Among Patients with Severe Asthma from the Chinese Societal Perspective. Applied Health Economics and Health Policy. 2026. doi:10.1007/s40258-026-01088-6
BibTeX
@article{Shi2026,
author = {Shi, Chaohao and Tan, Chongqing and Wan, Xiaomin and Wu, Meiyu and Meng, Kehui and Li, Andong and Zhang, Zixuan and Yi, Yangke and Liu, Qiao and Li, Jingjing},
title = {Cost-Effectiveness Analysis of Benralizumab Among Patients with Severe Asthma from the Chinese Societal Perspective},
journal = {Applied Health Economics and Health Policy},
year = {2026},
doi = {10.1007/s40258-026-01088-6}
}
EUVIMED